Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan Posted on November 14, 2023November 14, 2023 by KBD Admin
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults Posted on November 1, 2023November 3, 2023 by KBD Admin
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN) Posted on October 30, 2023November 3, 2023 by KBD Admin
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults Posted on October 19, 2023October 19, 2023 by KBD Admin
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC) Posted on October 13, 2023October 13, 2023 by KBD Admin
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11 Posted on October 6, 2023December 5, 2023 by KBD Admin
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) Posted on October 2, 2023October 2, 2023 by KBD Admin
Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis Posted on October 2, 2023October 2, 2023 by KBD Admin
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease Posted on October 2, 2023October 25, 2023 by KBD Admin
AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria Posted on September 27, 2023September 28, 2023 by KBD Admin
